» Articles » PMID: 20185037

Triage After Hospitalization with Advanced Heart Failure: the ESCAPE (Evaluation Study of Congestive Heart Failure and Pulmonary Artery Catheterization Effectiveness) Risk Model and Discharge Score

Overview
Date 2010 Feb 27
PMID 20185037
Citations 72
Authors
Affiliations
Soon will be listed here.
Abstract

Objectives: Identifying high-risk heart failure (HF) patients at hospital discharge may allow more effective triage to management strategies.

Background: Heart failure severity at presentation predicts outcomes, but the prognostic importance of clinical status changes due to interventions is less well described.

Methods: Predictive models using variables obtained during hospitalization were created using data from the ESCAPE (Evaluation Study of Congestive Heart Failure and Pulmonary Artery Catheterization Effectiveness) trial and internally validated by the bootstrapping method. Model coefficients were converted to an additive risk score. Additionally, data from FIRST (Flolan International Randomized Survival Trial) was used to externally validate this model.

Results: Patients discharged with complete data (n = 423) had 6-month mortality and death and rehospitalization rates of 18.7% and 64%, respectively. Discharge risk factors for mortality included BNP, per doubling (hazard ratio [HR]: 1.42, 95% confidence interval [CI]: 1.15 to 1.75), cardiopulmonary resuscitation or mechanical ventilation during hospitalization (HR: 2.54, 95% CI: 1.12 to 5.78), blood urea nitrogen, per 20-U increase (HR: 1.22, 95% CI: 0.96 to 1.55), serum sodium, per unit increase (HR: 0.93, 95% CI: 0.87 to 0.99), age >70 years (HR: 1.05, 95% CI: 0.51 to 2.17), daily loop diuretic, furosemide equivalents >240 mg (HR: 1.49, 95% CI: 0.68 to 3.26), lack of beta-blocker (HR: 1.28, 95% CI: 0.68 to 2.41), and 6-min walk, per 100-foot increase (HR: 0.955, 95% CI: 0.99 to 1.00; c-index 0.76). A simplified discharge score discriminated mortality risk from 5% (score = 0) to 94% (score = 8). Bootstrap validation demonstrated good internal validation of the model (c-index 0.78, 95% CI: 0.68 to 0.83).

Conclusions: The ESCAPE study discharge risk model and score refine risk assessment after in-hospital therapy for advanced decompensated systolic HF, allowing clinicians to focus surveillance and triage for early life-saving interventions in this high-risk population. (Evaluation Study of Congestive Heart Failure and Pulmonary Artery Catheterization Effectiveness [ESCAPE]; NCT00000619).

Citing Articles

A Potential Relationship Between HALP Score and In-Hospital Mortality in Acute Heart Failure.

Muge A, Cenan I, Nil O, Esenboga K Clin Cardiol. 2025; 48(3):e70108.

PMID: 40022549 PMC: 11871422. DOI: 10.1002/clc.70108.


Predictors of heart failure readmission and all-cause mortality in patients with acute heart failure.

Espersen C, Campbell R, Claggett B, Lewis E, Docherty K, Lee M Int J Cardiol. 2024; 406:132036.

PMID: 38599465 PMC: 11146586. DOI: 10.1016/j.ijcard.2024.132036.


The modified Rajan's heart failure risk score predicts all-cause mortality in patients hospitalized for heart failure with reduced ejection fraction: a retrospective cohort study.

Rajan R, Hui J, Al Jarallah M, Tse G, Chan J, Satti D Ann Med Surg (Lond). 2024; 86(4):1843-1849.

PMID: 38576988 PMC: 10990347. DOI: 10.1097/MS9.0000000000001646.


Sodium-Glucose Cotransporter-2 Inhibitors in Heart Failure with Malnutrition, Frailty, Sarcopenia, or Cachexia.

Horiuchi Y, Asami M, Yahagi K, Oshima A, Gonda Y, Yoshiura D J Clin Med. 2024; 13(6).

PMID: 38541895 PMC: 10970728. DOI: 10.3390/jcm13061670.


Analysis of the Larissa Heart Failure Risk Score: Predictive Value in 9207 Patients Hospitalized for Heart Failure from a Single Center.

Xanthopoulos A, Skoularigis J, Briasoulis A, Magouliotis D, Zajichek A, Milinovich A J Pers Med. 2023; 13(12).

PMID: 38138948 PMC: 10744973. DOI: 10.3390/jpm13121721.


References
1.
Aaronson K, Schwartz J, Chen T, Wong K, Goin J, Mancini D . Development and prospective validation of a clinical index to predict survival in ambulatory patients referred for cardiac transplant evaluation. Circulation. 1997; 95(12):2660-7. DOI: 10.1161/01.cir.95.12.2660. View

2.
Califf R, Adams K, McKenna W, Gheorghiade M, Uretsky B, McNulty S . A randomized controlled trial of epoprostenol therapy for severe congestive heart failure: The Flolan International Randomized Survival Trial (FIRST). Am Heart J. 1997; 134(1):44-54. DOI: 10.1016/s0002-8703(97)70105-4. View

3.
Brophy J, Dagenais G, McSherry F, Williford W, Yusuf S . A multivariate model for predicting mortality in patients with heart failure and systolic dysfunction. Am J Med. 2004; 116(5):300-4. DOI: 10.1016/j.amjmed.2003.09.035. View

4.
OConnor C, Hathaway W, Bates E, Leimberger J, Sigmon K, Kereiakes D . Clinical characteristics and long-term outcome of patients in whom congestive heart failure develops after thrombolytic therapy for acute myocardial infarction: development of a predictive model. Am Heart J. 1997; 133(6):663-73. DOI: 10.1016/s0002-8703(97)70168-6. View

5.
Kearney M, Nolan J, Lee A, Brooksby P, Prescott R, Shah A . A prognostic index to predict long-term mortality in patients with mild to moderate chronic heart failure stabilised on angiotensin converting enzyme inhibitors. Eur J Heart Fail. 2003; 5(4):489-97. DOI: 10.1016/s1388-9842(03)00053-9. View